These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3896215)

  • 21. Glucagon-stimulated and postprandial plasma C-peptide values as measures of insulin secretory capacity.
    Koskinen PJ; Viikari JS; Irjala KM
    Diabetes Care; 1988 Apr; 11(4):318-22. PubMed ID: 3042307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-obese adult onset diabetes with oral hypoglycemic agent failure: islet cell autoantibodies or reversible beta cell refractoriness?
    Sá JR; Silva RC; Nasri F; Aguade LC; Velloso L; Chacra AR; Dib SA
    Braz J Med Biol Res; 2003 Oct; 36(10):1301-9. PubMed ID: 14502361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
    Matthews DR; Boland O
    Metabolism; 1997 Dec; 46(12 Suppl 1):5-9. PubMed ID: 9439551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fasting, postprandial and postprandial plus glucagon-stimulated plasma C-peptide levels in non-insulin-dependent diabetics and in control subjects.
    Sarlund H; Laakso M; Pyörälä K; Penttilä I
    Acta Med Scand; 1987; 221(4):377-83. PubMed ID: 3604753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-C-peptide test as a measure of insulin requirement in type 2 diabetes: evaluation of stopping insulin therapy in eleven patients.
    Viikari J; Rönnemaa T; Koskinen P
    Ann Clin Res; 1987; 19(3):178-82. PubMed ID: 3314647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.
    Scheen AJ; Castillo MJ; Lefèbvre PJ
    Diabetes Metab; 1996 Dec; 22(6):397-406. PubMed ID: 8985647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiological study of the non-insulin-dependent phase of type I diabetes mellitus.
    Torella R; Salvatore T; Cozzolino D; Grandillo F; Giugliano D
    Acta Diabetol Lat; 1988; 25(2):161-72. PubMed ID: 3146849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes.
    Glaser B; Leibovich G; Nesher R; Hartling S; Binder C; Cerasi E
    Acta Endocrinol (Copenh); 1988 Jul; 118(3):365-73. PubMed ID: 3293339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment.
    Kärvestedt L; Andersson G; Efendic S; Grill V
    J Intern Med; 2002 Apr; 251(4):307-16. PubMed ID: 11952881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impaired insulin secretion in non-diabetic offspring of probands with latent autoimmune diabetes mellitus in adults.
    Vauhkonen I; Niskanen L; Knip M; Ilonen J; Vanninen E; Kainulainen S; Uusitupa M; Laakso M
    Diabetologia; 2000 Jan; 43(1):69-78. PubMed ID: 10663218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic significance of antibodies to glutamic acid decarboxylase in Japanese diabetic patients with secondary oral hypoglycemic agents failure.
    Fukui M; Nakano K; Maruya E; Saji H; Ohta K; Ohta M; Obayashi H; Mori H; Kajiyama S; Wada S; Shigeta H; Kitagawa Y; Nakamura N; Kondo M
    Clin Immunol Immunopathol; 1997 Nov; 85(2):182-6. PubMed ID: 9344701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B-cell responses to intravenous glucose and glucagon in non-diabetic twins of patients with type 1 (insulin-dependent) diabetes mellitus.
    Heaton DA; Lazarus NR; Pyke DA; Leslie RD
    Diabetologia; 1989 Nov; 32(11):814-7. PubMed ID: 2687066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents.
    Guevara-Aguirre J; Guevara M; Saavedra J; Mihic M; Modi P
    Diabetes Technol Ther; 2004 Feb; 6(1):1-8. PubMed ID: 15000763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas.
    Polo V; Saibene A; Pontiroli AE
    Acta Diabetol; 1998 Apr; 35(1):61-4. PubMed ID: 9625292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Latent autoimmune diabetes in adults(LADA): part of the clinical spectrum of type-1 diabetes mellitus of autoimmune origin].
    Pánczél P; Hosszúfalusi N; Bornemisza B; Horváth L; Jánoskuti L; Füst G; Rajczy K; Vatay A; Prohászka Z; Madácsy L; Luczay A; Blatniczky L; Halmos T; Körner A; Szilvási I; Romics L
    Orv Hetil; 2001 Nov; 142(46):2571-8. PubMed ID: 11770176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Secondary failure to oral hypoglycemic drugs: islet cell function determined by urinary C-peptide].
    Durruty P; García de los Rios M; López G
    Rev Med Chil; 1988 Apr; 116(4):301-7. PubMed ID: 3072638
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.